The Asclepius Innovation Prize

Awarded to the medical organization that introduced a clinically validated treatment or diagnostic method that materially changed the standard of care for a widespread condition.

OUR IMPACT

01.

Reduced average diagnostic time for early-stage pancreatic cancer from 14 months to 11 days

01.

Reduced average diagnostic time for early-stage pancreatic cancer from 14 months to 11 days

02.

Five-year survival rate for enrolled patients improved from 11% to 43%

02.

Five-year survival rate for enrolled patients improved from 11% to 43%

03.

Test now covered under 34 national health insurance frameworks

03.

Test now covered under 34 national health insurance frameworks

A Commitment to Clarity

Meridial's oncology research division developed the ClearMark liquid biopsy panel in partnership with three academic medical centers. The panel detects a novel set of circulating tumor markers with 94% sensitivity at stage I, a threshold previously considered unachievable without invasive tissue sampling. The Asclepius committee described the contribution as "a rare instance of a single institution bending the survival curve for one of medicine's most resistant diseases."

Create a free website with Framer, the website builder loved by startups, designers and agencies.